Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1140 in Advanced Malignancies
NCT03329950Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Dec 2017
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CDX-1140 in melanoma, non-small cell lung cancer (NSCLC), breast cancer and 22 more (4 arms), sponsored by Celldex Therapeutics. Primary endpoint: Safety and Tolerability. Started Dec 2017; status: completed.
02
Drugs
CDX-1140
03
Conditions
melanomanon-small cell lung cancer (NSCLC)breast cancergastric cancer (GC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03329950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329950.